Mineralys Therapeutics 株価情報 (NASDAQ: MLYS)

Mineralys Therapeutics (NASDAQ:MLYS) 株価情報

MINERALYS THERAPEUTICS INC

Mineralys Therapeutics

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics Inc

Macro Economic Events

News

Econ #s

Economics

US Imports (Mar) $419B: Prior $401.10B

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is down 0.5% over the past 24 hours as traders eye a potential local top one day before the Federal Reserve announces <a href="https://www.benzinga.com/25/05/45192387/market-bets-on-aggressive-fed-cuts-clash-with-short-rate-market-data-next-fed-chair-could-initiate-cutting-cycle-says-expert">its interest rate decision</a>
What Happened: Crypto trader Astronomer <a href="https://x.com/astronomer_zero/status/1919485112150065533?s=46">said</a> on Tuesday there's a chance Bitcoin may form a short-term top around the FOMC meeting. 
He cautions this signal is weak by itself and shouldn&#8217;t trigger trades without supporting data. 
The keyword is "may," reiterating his approach of acting only on firm signals and logic-based setups.
While FOMC events have historically triggered >85% accurate reversals, this time the strong quarterly uptrend could override that pattern. 
Astronomer estimates a 76% probability that BTC continues upward from current levels, with a 24% chance of a shallow pullback.
He warns against shorting here or prematurely exiting longs, framing any dip as a "compound opportunity" rather than a reason to panic.
The strategy remains focused, mentally prepared, and rooted in strong trade management consistent about earlier theories on price mechanics and stop-loss design.
Also Read: <a href="https://in.benzinga.com/markets/cryptocurrency/25/05/45191302/corporations-will-pour-330-billion-into-bitcoin-by-2029-bernstein">Corporations Will Pour $330 Billion Into Bitcoin By 2029: Bernstein</a>
What's Next: Crypto trader Titan of Crypto notes BTC is consolidating between last week's high and low ahead of the FOMC decision and Fed Chair Jerome Powell's speech. 
The daily MACD has flipped bearish, suggesting momentum may be fading.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> Short-Term Update &#x1f4a5;<a href="https://twitter.com/hashtag/BTC?src=hash&amp;ref_src=twsrc%5Etfw">#BTC</a> is consolidating between last week's high and low, awaiting tomorrow's FOMC meeting and Jerome Powell's speech. Meanwhile, the daily MACD is crossing bearish, signaling slowing momentum. <a href="https://t.co/UKA0Vjj5xB">pic.twitter.com/UKA0Vjj5xB</a>
&mdash; Titan of Crypto (@Washigorira) <a href="https://twitter.com/Washigorira/status/1919702726235111538?ref_src=twsrc%5Etfw">May 6, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
PattaTrades <a href="https://x.com/PattaTrades/status/1919711436617502760">highlights </a>that Bitcoin is trading back within a six-day composite range from before the monthly close. 
He's eyeing a potential sweep below $63,850 for long liquidations before entering new longs.
He expects muted volatility until after the FOMC, with range-bound setups preferred in the short term.  
Read Next:
<ul>
<li><a href="https://in.benzinga.com/markets/cryptocurrency/25/05/45196732/bitcoin-could-hit-450000-raoul-pal-says-dont-screw-this-up">Bitcoin Could Hit $450,000, Raoul Pal Says: &#8216;Don&#8217;t Screw This Up&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Dips Below $94,000 As Traders Eye Potential Short-Term Top

US Mar. Trade Balance $(140.50B) vs $(136.80B) Est.; Prior $(123.20B)

Baird analyst Michael Bellisario maintains Wyndham Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WH#NYSE">WH</a>) with a Outperform and lowers the price target from $107 to $99.

Price Target

Analyst Ratings

Baird Maintains Outperform on Wyndham Hotels & Resorts, Lowers Price Target to $99

IREN Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) (together with its subsidiaries, "IREN" or "the Company"), today published its monthly update for April 2025.
April&nbsp;Highlights
<ul>
<li>Mining capacity increased to 40 EH/s mid-month</li>
<li>On track for 50 EH/s&nbsp;by June 30</li>
<li>Miners scheduled to ship from Southeast Asia (during 90-day pause on reciprocal tariffs)</li>
<li>AI Cloud Services revenue continuing to&nbsp;grow</li>
<li>Horizon 1 AI Data Center on track for H2 2025 delivery</li>
<li>Customer and financing workstreams progressing</li>
</ul>

IREN

IREN Shares April 2025 Monthly Update; Mining Capacity Increased To 40 EH/s Mid-Month, On Track For 50 EH/s By June 30

Baird analyst Peter Benedict maintains Freshpet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPT#NASDAQ">FRPT</a>) with a Outperform and lowers the price target from $125 to $115.

FRPT

Baird Maintains Outperform on Freshpet, Lowers Price Target to $115

Needham analyst Ami Fadia reiterates Harmony Biosciences Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRMY#NASDAQ">HRMY</a>) with a Buy and maintains $49 price target.

Reiteration

HRMY

Needham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $49 Price Target

<a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1543151/000155278125000160/e25191_uber-8k.htm" title="https://www.sec.gov/ix?doc=/Archives/edgar/data/1543151/000155278125000160/e25191_uber-8k.htm">https://www.sec.gov/ix?doc=/Archives/edgar/data/1543151/000155278125000160/e25191_uber-8k.htm</a>

UBER

Uber Technologies To Acquire 85% Controlling Stake In Trendyol GO Online Meal And Grocery Delivery Business In Turkiye For ~$700M

Small Cap Consumer Research analyst Eric Beder reiterates a.k.a. Brands Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKA#NYSE">AKA</a>) with a Buy and maintains $30 price target.

Small Cap Consumer Research Reiterates Buy on a.k.a. Brands Holding, Maintains $30 Price Target

WIIM

DDOG

DDOG stock has given up its prior gain. Datadog shares were trading higher after the company reported better-than-expected Q1 results and raised its FY25 guidance.

Billionaire investor Bill Ackman isn't just writing a $900 million check to Howard Hughes Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HHH#NYSE">HHH</a>) &#8211; he's rewriting the script.
In a move that caught Wall Street's eye, Pershing Square, backed mainly by Ackman himself, is investing in Howard Hughes at $100 a share &#8211; a 48% premium over its May 2 close of $67.47. The punchline? Ackman's not going for a full buyout. Instead, he's installing himself as executive chairman and bringing his trusted lieutenant Ryan Israel along as chief investment officer.
Related: <a href="https://www.benzinga.com/25/05/45199902/bill-ackman-strikes-deal-to-form-mini-version-of-berkshire-hathaway-a-free-money-generating-company-he-wouldnt-bet-against">Bill Ackman Aims To Mimic Buffett, Berkshire Blueprint With $900M Howard Hughes Bet</a>
For Ackman, this is more than just a financial play – it's about transforming Howard Hughes into a diversified holding company, with future acquisitions likely in industries like insurance. While the real estate game remains Howard Hughes's core, Ackman aims to breathe new life into the company, one strategic deal at a time.
JPMorgan analyst Anthony Paolone is bullish on the stock, calling this deal a transformational shift. The new agreement cuts Pershing's annual fees to a modest $15 million, down from the previous proposal's $60 million, while linking additional fees to actual equity growth. With a target price of $82, Ackman could earn $29 million – half of what the previous plan would have cost. But there's a catch: Howard Hughes's real estate assets remain tough to value, and the stock will likely continue to trade below its net asset value (NAV), pegged at $90 by JPMorgan.
So, while Ackman may have a playbook, will he be able to execute it? That's the $900 million question.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506"><img loading="lazy" decoding="async" width="633" height="489" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06061641/Screenshot-2025-05-06-at-3.46.28-PM.png" alt="" class="wp-image-902951" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06061641/Screenshot-2025-05-06-at-3.46.28-PM.png 633w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06061641/Screenshot-2025-05-06-at-3.46.28-PM-300x232.png 300w" sizes="(max-width: 633px) 100vw, 633px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506">Chart created using Benzinga Pro</a>
On the technical side, Howard Hughes is showing mixed signals. The stock price is currently $69.40, above the 8-day simple moving average (SMA) of $67.75, suggesting short-term bullish momentum. The 20-day SMA of $66.43 also signals a positive outlook.
The 50-day SMA of $71.34 and the 200-day SMA of $74.94 point to bearish pressure in the longer term. The Moving Average Convergence Divergence (MACD) indicator is at a negative 0.91, signaling a bearish outlook, while the Relative Strength Index (RSI) at 53.09 suggests a neutral stance.
In short, Howard Hughes is caught between bullish short-term signals and bearish longer-term pressure. To gauge the next move, traders will need to watch for a break above the 50-day SMA or a dip below the 200-day SMA.
Keep an eye on the stock as Ackman's strategy unfolds. The earnings report on May 7 will be the next key test.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45193861/3-stocks-warren-buffett-first-bought-24-years-ago-hint-apples-not-one-of-them">3 Stocks Warren Buffett First Bought 24 Years Ago (Hint: Apple&#8217;s Not One Of Them)&#8217;</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Hedge Funds

Technicals

Previews

Trading Ideas

Bill Ackman's $900M Boost Could Lift Howard Hughes Stock Above Key Technical Barrier Ahead Of Q1 Earnings

Guidance

Embraer-Empresa Brasileira De Aeronautica

Embraer Affirms FY25 Sales Guidance Of $7.00B-$7.50B vs $7.34B Estimate

Biotech

Legal

General

WINT

Windtree Therapeutics Received Advice From Intellectual Property And FDA Experts; Istaroxime May Receive New Chemical Entity Designation; Istaroxime Has USPTO Issued Method Of Patent Providing Protection Until 2039 And Pedning Method Of Using Patent Providing Protection Until 2043

Embraer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERJ#NYSE">ERJ</a>) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $0.03 by 1433.33 percent. This is a 471.43 percent decrease over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $1.10 billion which missed the analyst consensus estimate of $1.18 billion by 6.63 percent. This is a 23.02 percent increase over sales of $896.60 million the same period last year.

Earnings

Earnings Misses

Embraer Q1 Adj. EPS $(0.40) Misses $0.03 Estimate, Sales $1.10B Miss $1.18B Estimate

As of May 6, 2025, two stocks in the energy sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Teekay Tankers Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNK#NYSE">TNK</a>)</h3>
<ul>
<li>Teekay will release their financial results for the first quarter after the closing bell on Wednesday, May 7. Analysts expect the company to report quarterly earnings at $1.15 per share on revenue of $144.85 million. The company's stock jumped around 23% over the past month and has a <a href="https://www.benzinga.com/quote/TNK">52-week high of $74.20</a>.</li>
<li>RSI Value: 73.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>TNK Price Action: Shares of Teekay Tankers jumped 4.7% to close at $46.17 on Monday.</li>
<li>Edge Stock Ratings: 27.51 Momentum score with Value at 94.71. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/TNK"><img loading="lazy" decoding="async" width="491" height="172" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06045245/image-48.png" alt="" class="wp-image-902800" style="width:377px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06045245/image-48.png 491w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06045245/image-48-300x105.png 300w" sizes="(max-width: 491px) 100vw, 491px" /></a></figure>
<h3 class="wp-block-heading">Frontline Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>)</h3>
<ul>
<li>On April 22, Evercore ISI Group analyst Jonathan Chappell maintained Frontline with an Outperform rating and lowered the price target from $22 to $20. The company's stock gained around 24% over the past month and <a href="https://www.benzinga.com/quote/FRO">has a 52-week high</a> of $29.39.</li>
<li>RSI Value: 70.5</li>
<li>FRO Price Action: Shares of Frontline gained 3.9% to close at $17.79 on Monday.</li>
</ul>
Curious about other BZ Edge Rankings? Click here to discover <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">how similar stocks measure up</a>. 
Read This Next:<a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more">Jim Cramer Says Applied Materials Is An &#8216;Excellent&#8217; Company, But Likes This Tech Stock More</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

Markets

Top 2 Energy Stocks That Are Ticking Portfolio Bombs

FOXO

FOXO Technologies Says Its Myrtle Recovery Centers Subsidiary Has Seen Over 400 Patients Since Aug. 2023

AMETEK, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AME#NYSE">AME</a>) and FARO Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) today announced that they have entered into a definitive agreement under which AMETEK will acquire all outstanding shares of FARO Technologies common stock for $44 per share in cash, which represents an approximate 40% premium to FARO's closing price on May 5, 2025. The transaction values FARO at an enterprise value of approximately $920 million. The boards of directors of both companies have unanimously approved the transaction.
Founded in 1981 and headquartered in Lake Mary, Florida, FARO Technologies is a leading provider of 3D measurement and imaging solutions, including portable measurement arms, laser scanners and trackers, software solutions, and comprehensive service offerings. FARO's precision manufacturing and digital reality solutions serve a diverse range of end markets. The company has annual sales of approximately $340 million.

FARO

AMETEK And FARO Technologies Have Entered Into A Definitive Agreement Under Which AMETEK Will Acquire All Outstanding Shares Of FARO Technologies Common Stock For $44 Per Share In Cash, Or An Enterprise Value Of ~$920M

Camden National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAC#NASDAQ">CAC</a>) reported quarterly earnings of $0.95 per share which missed the analyst consensus estimate of $0.99 by 4.04 percent. This is a 10.47 percent increase over earnings of $0.86 per share from the same period last year. The company reported quarterly sales of $60.05 million which beat the analyst consensus estimate of $57.78 million by 3.94 percent. This is a 44.38 percent increase over sales of $41.59 million the same period last year.

Earnings Beats

Camden National Q1 Adj. EPS $0.95 Misses $0.99 Estimate, Sales $60.05M Beat $57.78M Estimate

Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) will release earnings results for the first quarter, after the <a href="https://www.benzinga.com/quote/amd/earnings">closing bell on Tuesday, May 6.</a>
Analysts expect the Santa Clara, California-based company to report quarterly earnings at 93 cents per share, up from 62 cents per share in the year-ago period. AMD projects to report quarterly revenue at $7.12 billion, compared to $5.47 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Advanced Micro Devices, on April 9, announced the new Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google Cloud C4D and H4D virtual machines (VMs), which fifth-generation AMD EPYC processors power.
AMD shares gained 1.8% to close at $100.59 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/amd/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Stifel analyst Ruben Roy maintained a Buy rating and cut the price target from $162 to $132 on April 28, 2025. This analyst has an accuracy rate of 78%.</li>
<li>Susquehanna analyst Christopher Rolland maintained a Positive rating and cut the price target from $150 to $135 on April 24, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Wedbush analyst Matt Bryson maintained an Outperform rating and slashed the price target from $150 to $115 on April 23, 2025. This analyst has an accuracy rate of 79%.</li>
<li>Bernstein analyst Stacy Rasgon maintained a Market Perform rating and cut the price target from $125 to $95 on April 22, 2025. This analyst has an accuracy rate of 71%.</li>
<li>UBS analyst Timothy Arcuri maintained a Buy rating and lowered the price target from $175 to $155 on April 17, 2025. This analyst has an accuracy rate of 75%.</li>
</ul>
Considering buying AMD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="613" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06035814/image-43-1024x613.png" alt="" class="wp-image-902688" style="width:631px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06035814/image-43-1024x613.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06035814/image-43-300x180.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06035814/image-43-768x460.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06035814/image-43.png 1107w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45193793/top-3-tech-and-telecom-stocks-that-may-jump-this-quarter">Top 3 Tech And Telecom Stocks That May Jump This Quarter</a> </li>
</ul>
Photo via Shutterstock

GOOG

GOOGL

Top Wall Street Forecasters Revamp AMD Motor Expectations Ahead Of Q1 Earnings

Needham analyst Joseph Stringer reiterates Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) from Hold to Hold.

VRTX

Needham Reiterates Hold on Vertex Pharmaceuticalsto Hold

Press Releases

Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

Health Care

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo

Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)

Comments

Mineralys Therapeutics

ニュース

パートナーシップ

ベンジンガ・グローバル